UNH

UnitedHealth Group Inc. 2007 Annual Report (10-K) Summary

Business Context and Reporting Period

This Form 10-K covers the fiscal year ended December 31, 2007. UnitedHealth Group is a diversified health and well-being company serving approximately 70 million Americans. The company manages roughly $100 billion in aggregate health care spending. In the fourth quarter of 2007, the company transitioned to a new four-segment reporting structure: Health Care Services (Commercial Markets, Ovations, AmeriChoice), OptumHealth, Ingenix, and Prescription Solutions (formerly part of Ovations).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Consolidated revenues increased 5% to $75.4 billion, driven by premium rate increases and growth in individuals served, partially offset by a 4% decrease in commercial risk-based members due to competitive pricing.
• Profitability: Net earnings rose 12% to $4.7 billion. Operating margin improved to 10.4% from 9.8% due to productivity gains and a lower medical care ratio (80.6% vs 81.2%).
• Segment Performance:
  • Prescription Solutions: Revenues surged 224% to $13.2 billion following the inclusion of Medicare Part D members.
  • Ingenix: Revenues grew 36% and operating earnings grew 51% due to new business in health information and contract research.
  • Health Care Services: Revenues increased 5% to $71.2 billion; operating earnings rose 13%.
• Capital Structure: Total debt increased significantly to $11.0 billion (from $7.5 billion) as the company increased its debt-to-total-capital ratio target to the 40% range. This resulted in debt rating downgrades by S&P, Moody's, and Fitch in late 2007/early 2008.
• Unusual Items: Operating costs included a $176 million charge (Section 409A) related to historical stock option practices.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects a slight decline in investment income in 2008 due to lower interest rates. The company plans to repurchase approximately $5 billion of common stock in 2008.
• Medical Cost Sensitivity: A hypothetical 1% increase in commercial insured medical costs would reduce 2007 net earnings by approximately $190 million.
• Regulatory Risks: The company faces ongoing investigations by the SEC, U.S. Attorney for the Southern District of New York, and the Minnesota Attorney General regarding historical stock option practices. There are also routine audits by CMS and state regulators.
• Legal Contingencies: Significant litigation includes shareholder derivative actions, a federal securities class action, and an ERISA class action related to stock options. Additionally, the company is defending against provider reimbursement lawsuits (e.g., AMA lawsuit) and potential New York Attorney General action.
• Medicare Part D Risk: Changes to the Medicare Part D risk-sharing provisions in 2008 mean the company retains more risk (50-80% of losses/profits outside the corridor) compared to the prior year.

Investor Verification Checklist

• Medical Cost Development: Verify the accuracy of the $420 million favorable medical cost development recorded for prior years and the sensitivity of future estimates to completion factors.
• Stock Option Litigation: Monitor the status of the Special Litigation Committee settlements and potential additional cash/non-cash charges from regulatory inquiries.
• Debt Ratings and Covenants: Confirm compliance with the 50% debt-to-total-capital covenant and assess the impact of recent rating downgrades on borrowing costs.
• Medicare Part D Enrollment: Review the impact of losing auto-enrolled low-income subsidy members in 2008 due to bid thresholds.
• Segment Margins: Analyze the low operating margin (2.0%) of the Prescription Solutions segment compared to other segments.